Synaptogenix, INC 8-K filings

TAO Synergies Inc. stockholders approved an increase of 500,000 shares to its 2020 Equity Incentive Plan, authorized common stock issuance for convertible securities, and re-elected a director at its Annual Meeting.

TAO Synergies Inc. announced an $11 million private placement of Series E convertible preferred stock and warrants, backed by existing investors, James Altucher, and new strategic investor DCG, to fund general corporate purposes and working capital.

TAO Synergies Inc. announced board resignations and a new appointment, alongside engaging Joseph Jacks as an advisor for its AI-focused crypto treasury strategy.

TAO Synergies Inc. stockholders approved a significant increase in the company's equity incentive plan shares and authorized the issuance of common stock underlying convertible preferred stock and warrants.

TAO Synergies Inc. announced the accumulation of 42,111 Bittensor (TAO) tokens, solidifying its position as a leading decentralized AI digital asset treasury company.

A digital asset treasury company announced a significant acquisition of decentralized AI tokens, positioning itself as the largest publicly traded pure-play holder in the Bittensor ecosystem.

Synaptogenix, Inc. has officially changed its name to TAO Synergies Inc. and will trade under the new Nasdaq ticker symbol TAOX, signaling a strategic pivot to an AI-focused cryptocurrency treasury strategy centered on the TAO token.

Synaptogenix, Inc. announced its initial purchase of TAO, an AI-focused cryptocurrency, and partnered with BitGo for secure custody, staking, and trading services, commencing revenue generation through TAO staking.

Synaptogenix, Inc. announced a $5.5 million private placement to fund a new cryptocurrency treasury strategy focused on Bittensor TAO, alongside significant executive leadership changes.

Synaptogenix has formed a special committee to explore strategic opportunities to enhance value for investors, supported by a strong cash position and reduced burn rate.

Synaptogenix held its annual meeting on December 6, 2024, where stockholders voted on the election of directors, authorization to issue stock, an amendment to the equity incentive plan, and the ratification of the company's accounting firm.

Synaptogenix, Inc. has changed its independent registered public accounting firm from Morison Cogen LLP to Stephano Slack LLC, effective October 4, 2024.

Synaptogenix, Inc. has filed a Certificate of Designations creating a new Series C Convertible Preferred Stock and completed a $5 million private placement.

Synaptogenix, a biopharmaceutical company, has announced a $5 million financing agreement with existing investors through a combination of a registered offering and a private placement.

Synaptogenix has extended the maturity date of its Series B Convertible Preferred Stock from August 31, 2024, to September 9, 2024, with potential for further extensions.

Synaptogenix, Inc. has extended the employment term of its CEO, Dr. Alan J. Tuchman, through December 7, 2024, with automatic monthly renewals thereafter.

Synaptogenix has completed a 1-for-25 reverse stock split to increase its share price and maintain its Nasdaq listing.